The dynamics of hepcidin‐ferroportin internalization and consequences of a novel ferroportin disease mutation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The hepcidin‐ferroportin axis underlies the pathophysiology of many iron‐associated disorders and is a key target for the development of therapeutics for treating iron‐associated disorders. The aims of this study were to investigate the dynamics of hepcidin‐mediated ferroportin internalization and the consequences of a novel disease‐causing mutation on ferroportin function. Specific reagents for ferroportin are limited; we developed and characterized antibodies against the largest extracellular loop of ferroportin and developed a novel cell‐based assay for studying hepcidin‐ferroportin function. We show that hepcidin‐mediated ferroportin internalization is a rapid process and could be induced using low concentrations of hepcidin. Targeted next‐generation sequencing utilizing an iron metabolism gene panel developed in our group identified a novel ferroportin p.D84E variant in a patient with iron overload. Wild‐type and mutant ferroportin constructs were generated, transfected into HEK293 cells and analysed using an all‐in‐one flow‐cytometry‐based assay to study the effects on hepcidin‐mediated internalization and iron transport. Consistent with the classical phenotype of ferroportin disease, the p.D84E mutation results in an inability to transport iron and hepcidin insensitivity. These results validate a recently proposed 3D‐structural model of ferroportin and highlight the significance of this variant in the structure and function of ferroportin. Our novel ferroportin antibody and assay will be valuable tools for investigating the regulation of hepcidin/ferroportin function and the development of novel approaches for the therapeutic modulation of iron homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113468 · Cited by 557
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin
Drakesmith, H., Schimanski, L. M., Ormerod, E., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0561 · Cited by 264
The molecular basis of ferroportin-linked hemochromatosis
De Domenico, I., Ward, D. M., Nemeth, E., Vaughn, M. B., Musci, G., Ganz, T., & Kaplan, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503804102 · Cited by 230
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212
Ross, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145 · cited 1×
“mechanisms involved in hepcidin-mediated ferroportin internalization.(12) We have generated a novel antibody directed against the largest extracellular loop of ferroportin; we show that it is highly specific and detects cell surface-exposed ferroportin by immunofluorescence”
Ferroportin disease: a systematic meta-analysis of clinical and molecular findings
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.016 · Cited by 133 · cited 3×
“Interestingly, SLC40A1 mutations can lead to one of two distinct phenotypes, characterized by differing patterns of iron overload due to either defects in ability to transport iron or its response to hepcidin.(6) Iron transport-defective mutations lead to the classical phenotype of ferroportin disease (HH type 4A): ir…”
InfluentialTaniguchi, R., Kato, H. E., Font, J., Deshpande, C. N., Wada, M., Ito, K., Ishitani, R., Jormakka, M., & Nureki, O. (2015) · Nature Communications · doi:10.1038/ncomms9545 · Cited by 120
Mayr, R., Griffiths, W. J. H., Hermann, M., McFarlane, I., Halsall, D. J., Finkenstedt, A., Douds, A., Davies, S. E., Janecke, A. R., Vogel, W., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.064 · Cited by 64
Cited by
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151
Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W. (2019) · Pharmaceuticals · doi:10.3390/ph12030132 · Cited by 57
“Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27 Asp84Glu – ↓ no – – 1 [43] Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79] Asp181Asn PM ↓ no no – 6 6 [51] Asp181Val ↓PM ↓ no no – 10 10 [8,42,46,80] Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]”
Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction
Ross, S. L., Biswas, K., Rottman, J., Allen, J. R., Long, J., Miranda, L. P., Winters, A., & Arvedson, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00838 · Cited by 33
Guellec, J., Elbahnsi, A., Tertre, M. L., Uguen, K., Gourlaouen, I., Férec, C., Ka, C., Callebaut, I., & Gac, G. L. (2019) · The FASEB Journal · doi:10.1096/fj.201901857r · Cited by 21
Metadata
- Authors
- Wallace, D. F., McDonald, C. J., Ostini, L., Iser, D., Tuckfield, A., & Subramaniam, V. N.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2017-07-29
- Volume
- 92
- Issue
- 10
- Pages
- 1052-1061
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2734249968
- Cited by
- 21
- References
- 8
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.